NCT02045602View on ClinicalTrials.gov

Phase I Dose Escalation Study of Intravenous VCN-01 With or Without Gemcitabine and Abraxane® in Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

May 31, 2019

Study Completion Date

January 31, 2020

Conditions

Locally Advanced Solid TumorsMetastatic Solid TumorsPancreatic Adenocarcinoma

Interventions

GENETIC

VCN-01

Genetically modified human adenovirus encoding human PH20 hyaluronidase

DRUG

Gemcitabine

1000 mg/m2 intravenous administration

DRUG

Abraxane®

125 mg/m2 intravenous administration

Trial Locations (5)

25080

Centro Integral Oncológico Clara Campal, Madrid

28034

Hospital Universitario Ramón y Cajal, Madrid

28041

Hospital Universitario 12 de Octubre, Madrid

08035

Hospital Vall d'Hebron, Barcelona

08908

Institut Català d'Oncologia, L'Hospitalet de Llobregat

All Listed Sponsors

lead

Theriva Biologics SL

INDUSTRY

NCT02045602 - Phase I Dose Escalation Study of Intravenous VCN-01 With or Without Gemcitabine and Abraxane® in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter